How it works
A synthetic analogue of the immunopeptide tuftsin. It modulates GABA-A expression, inhibits enkephalin degradation and shifts the balance of monoamine neurotransmitters, producing calm without benzodiazepine-like sedation.
Structure: Heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro)
Reported benefits
- Anxiolytic effect without sedation or dependence
- Improved stress resilience
- Mild cognitive and immune modulation
Practical considerations
- Often paired with Semax for calm focus
- Western clinical evidence is minimal
- Effect size is modest
Side effects and risks
- Nasal irritation
- Occasional drowsiness
- Rare mood flattening
Selank dosing overview
250–750 mcg daily in divided doses, 2–4 week cycles
| Context | Amount | Frequency | Route |
|---|---|---|---|
| Commonly cited protocol | 250–750 mcg | Daily in divided doses, 2–4 week cycles | Intranasal |
This describes doses reported in published literature and community protocols. It is not a recommendation, and it is not a substitute for clinical supervision.
Selank FAQ
What is Selank used for?
It is a tuftsin analogue studied in Russia for generalised anxiety, described as anxiolytic without the sedation or dependence associated with benzodiazepines.
How does it differ from Semax?
Both are Russian nasal peptides, but Selank targets anxiety and GABA/serotonin modulation while Semax is aimed at attention, BDNF and neuroprotection.
Is the anxiolytic evidence strong?
The supporting trials are small and largely Russian-published, with limited independent replication. Treat the effect size as unestablished.
Research references
- Zozulya et al., 2008 — Selank in generalised anxiety disorder